Hairy Cell Leukemia Market Size
| Study Period | 2018 - 2028 |
| Base Year For Estimation | 2022 |
| Forecast Data Period | 2023 - 2028 |
| CAGR | 5.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hairy Cell Leukemia Market Analysis
The hairy cell leukemia market is expected to grow at a CAGR of 5.0% during the forecast period.
The COVID-19 pandemic had a significant impact on the market studied. Cancer treatments such as chemotherapy and immune suppressants typically damage the patient's immune system. This weakened immune system of the target population is expected to create a risk of COVID-19 infection. Various studies have been conducted to determine the impact of COVID-19 on leukemia patients. According to a research article published in September 2021, chronic lymphocytic leukemia (CLL) patients are more susceptible to serious infections due to the immunodeficiency caused by the disease and its therapy, and COVID-19 continued to have a high admission rate even among consecutive and young early-stage CLL patients. However, with the restrictions released and treatment services resumed, the demand for leukemia treatment is expected to increase, driving market growth over the forecast period.
Certain factors that are expected to propel market growth are the growing burden of leukemia cases, the increasing diagnosis rate, and the growing geriatric population. In addition, the elderly population is at high risk of developing leukemia, which is also expected to increase the demand for effective treatment options, thereby increasing the demand for its treatment. For example, according to data published by the Mayo Clinic in 2022, hairy cell leukemia typically affects people in their 50s or 60s. In addition, as per the same source, men are more likely to be affected by hairy cell leukemia than women.
Furthermore, according to an article published in October 2021, it has been observed that chronic lymphocytic leukemia (CLL) is one of the most frequent kinds of leukemia, with an age-adjusted incidence of 4.9 per 100,000 people per year. As per the same source, only 9.1% of CLL patients are under the age of 45, and the median age at diagnosis is 70 years. Thus, all the aforesaid factors are expected to propel market growth over the forecast period.
On the contrary, the lack of awareness and limited health services in rural hospitals are expected to hinder market growth over the forecast period.
Hairy Cell Leukemia Market Trends
This section covers the major market trends shaping the Hairy Cell Leukemia Market according to our research experts:
Chemotherapy Segment is Expected to Register a Significant Growth Over the Forecast Period
The chemotherapy segment is expected to witness significant growth in the hairy cell leukemia market over the forecast period. The key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. Chemotherapy drugs, specifically purine analogs such as cladribine and pentostatin, are considered an initial treatment option for most individuals with hairy cell leukemia. Additionally, the increase in funding for companies and rising focus on adopting various business strategies such as partnerships, and conducting clinical trials related to hairy cell leukemia is expected to boost the studied market. For instance, in November 2021, the Leukemia and Lymphoma Society and Hairy Cell Leukemia Foundation announced a five-year, USD 10 million partnership in support of research on hairy cell leukemia (HCL), a rare hematological malignancy that infiltrates the blood, spleen, bone marrow, and other organs. As part of the collaboration, the two organizations collaborated on the HCL 2025 grants program, which aims to improve patient outcomes by gaining a deeper understanding of hairy cell leukemia.
Therefore, owing to the factors mentioned above, the studied segment is predicted to witness growth over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Have the Significant Market Share in the Hairy Cell Leukemia Market Over the Forecast Period
North America is anticipated to witness significant growth in the hairy cell leukemia market over the forecast period. Among other countries in the region, the United States is leading the market due to high healthcare expenditure, research, and development activities, and a rising prevalence of Chronic Lymphocytic Leukemia (CLL) and hairy cell leukemia. Additionally, the rising geriatric population across the United States is the primary driver for the hairy cell leukemia market in the region.
The rising prevalence of chronic lymphocytic leukemia is also expected to increase the risk of developing hairy cell leukemia among the population. For instance, as per the 2022 data published by the American Cancer Society, nearly 60,650 new cases of leukemia (all kinds) are estimated to be diagnosed in 2022, among which chronic lymphocytic leukemia (CLL) accounts for approximately 20,160 new cases. Additionally, as per the same source, about 1/4th of newly diagnosed cases of leukemia are CLL. Also, as per the 2021 data published by the NORD, about 6,000 persons are affected by hairy cell leukemia, and approximately 600-800 new cases are diagnosed in the United States every year. Thus, the increasing burden of leukemia cases among the population is anticipated to increase the demand for effective treatment and therapies which in turn is expected to boost the market growth.
Furthermore, most people with CLL are older individuals typically of age 70 years old when they receive a diagnosis. In addition, the data updated in February 2022 by HealthyPeople.gov, the United States HHS shows that the population in the United States is aging unprecedently and the population aged 65 or older is projected to reach 23.5% (98 million) by 2060 in the country. Thus, with the increasing geriatric population, the risk of developing hairy cell leukemia, a type of chronic lymphocytic leukemia is raising which is expected to increase the demand for the availability of drugs and therapy for the treatment of hairy cell leukemia which in turn is anticipated to boost the market growth over the forecast period.
With the increasing pharmaceutical spending on research and development, the adoption of various business strategies, and advanced technology for developing treatments and therapies is expected to boost the market growth in the region. For instance, according to the 2022 data published by the Organisation for Economic Co-operation and Development (OECD), the United States and Canada spent 3.4% and 1.60% of their GDP on research and development activities in 2021. Thus, the high investment in research and development by the countries further increases the company activities, thereby supporting market growth.
Therefore, owing to the factors mentioned above, North America is predicted to witness growth over the forecast period.
To understand geography trends, Download Sample Report
Hairy Cell Leukemia Industry Overview
The hairy cell leukemia market is competitive and many of the global players are in the market. Some of the companies in the market are Amgen Inc, AstraZeneca plc, BioGenomics Limited, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Merck KGaA, Merck & Co, Inc., and Pfizer Inc. are providing these products across the globe.
Hairy Cell Leukemia Market Leaders
AstraZeneca PLC
F. Hoffmann-La Roche Ltd
Merck KGaA
Johnson and Johnson
Pfizer, Inc.
*Disclaimer: Major Players sorted in no particular order
Hairy Cell Leukemia Market News
- August 2022: The FDA approved a tablet version of a drug called Calquence for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and previously treated relapsed or refractory mantle cell lymphoma (MCL), developed by AstraZeneca.
- May 2022: The University of Giessen has been conducting a Phase II/III clinical study to assess the efficacy and side effects of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia.
Hairy Cell Leukemia Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Leukemia Cases and Increase in Diagnosis Rates
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Awareness and Limited Health Services in Rural Hospitals
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapy
5.1.1 Chemotherapy
5.1.2 Targeted Therapy
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Rest of the World
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 AstraZeneca PLC
6.1.3 Gilead Sciences
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Astellas Pharma
6.1.6 Johnson & Johnson
6.1.7 Merck KGaA
6.1.8 Merck & Co. Inc.
6.1.9 Pfizer Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Hairy Cell Leukemia Industry Segmentation
As per the scope of the report, hairy cell leukemia is a type of blood cancer associated with the accumulation of abnormal lymphocytes. Overproduction and accumulation of hairy cells cause a deficiency of normal blood cells. The hairy cell leukemia market is segmented by therapy (chemotherapy and targeted therapy) and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Therapy | |
| Chemotherapy | |
| Targeted Therapy |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of the World |
Hairy Cell Leukemia Market Research FAQs
What is the current Hairy Cell Leukemia Market size?
The Hairy Cell Leukemia Market is projected to register a CAGR of 5.0% during the forecast period (2023-2028).
Who are the key players in Hairy Cell Leukemia Market?
AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Merck KGaA, Johnson and Johnson and Pfizer, Inc. are the major companies operating in the Hairy Cell Leukemia Market.
Which is the fastest growing region in Hairy Cell Leukemia Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Hairy Cell Leukemia Market?
In 2023, the North America accounts for the largest market share in the Hairy Cell Leukemia Market.
Hairy Cell Leukemia Industry Report
Statistics for the 2023 Hairy Cell Leukemia market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hairy Cell Leukemia analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Hairy Cell Leukemia Report Snapshots
